APO Research
Talk to an analyst

APO RESEARCH · REPORT

Skin Cancer Diagnostics Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Skin Cancer Diagnostics Therapeutics Market Outlook and Growth Opportunities 2026

31 December 2025194 pages

Choose your research edition.

Industry ResearchSkin Cancer Diagnostics Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Skin Cancer Diagnostics Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Skin Cancer Diagnostics Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Skin Cancer Diagnostics Therapeutics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Skin Cancer Diagnostics Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Skin Cancer Diagnostics Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Skin Cancer Diagnostics Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Skin Cancer Diagnostics Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Skin Cancer Diagnostics Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Skin Cancer Diagnostics Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Skin Cancer Diagnostics Therapeutics market include Abbott, Merck & Co., Inc., GlaxoSmithKline, Amgen, Sun Pharmaceutical Industries Ltd., Qiagen NV, Novartis AG, F. Hoffmann-La Roche Ltd and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Skin Cancer Diagnostics Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Skin Cancer Diagnostics Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Skin Cancer Diagnostics Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Skin Cancer Diagnostics Therapeutics market.

Skin Cancer Diagnostics Therapeutics Segment by Company

Abbott

Merck & Co., Inc.

GlaxoSmithKline

Amgen

Sun Pharmaceutical Industries Ltd.

Qiagen NV

Novartis AG

F. Hoffmann-La Roche Ltd

Bristol-Myers Squibb Company

AstraZeneca PLC

Skin Cancer Diagnostics Therapeutics Segment by Type

Melanoma

Non-melanoma

Skin Cancer Diagnostics Therapeutics Segment by Application

Hospital

Clinic

Other

Skin Cancer Diagnostics Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Skin Cancer Diagnostics Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Skin Cancer Diagnostics Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Skin Cancer Diagnostics Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Skin Cancer Diagnostics Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Skin Cancer Diagnostics Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Skin Cancer Diagnostics Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Skin Cancer Diagnostics Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Skin Cancer Diagnostics Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Skin Cancer Diagnostics Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Skin Cancer Diagnostics Therapeutics industry.

Chapter 3: Detailed analysis of Skin Cancer Diagnostics Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Skin Cancer Diagnostics Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Skin Cancer Diagnostics Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Skin Cancer Diagnostics Therapeutics Industry Trends Table 2. Skin Cancer Diagnostics Therapeutics Industry Drivers Table 3. Skin Cancer Diagnostics Therapeutics Industry Opportunities and Challenges Table 4. Skin Cancer Diagnostics Therapeutics Industry Restraints Table 5. Global Skin Cancer Diagnostics Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Skin Cancer Diagnostics Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Skin Cancer Diagnostics Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Skin Cancer Diagnostics Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Skin Cancer Diagnostics Therapeutics Company, Product Type & Application Table 10. Global Skin Cancer Diagnostics Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Skin Cancer Diagnostics Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Melanoma Table 15. Significant Companies of Non-melanoma Table 16. Global Skin Cancer Diagnostics Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Skin Cancer Diagnostics Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Skin Cancer Diagnostics Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Skin Cancer Diagnostics Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Skin Cancer Diagnostics Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Skin Cancer Diagnostics Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Skin Cancer Diagnostics Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Skin Cancer Diagnostics Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Skin Cancer Diagnostics Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Skin Cancer Diagnostics Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Skin Cancer Diagnostics Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Skin Cancer Diagnostics Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Skin Cancer Diagnostics Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Skin Cancer Diagnostics Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Abbott Company Information Table 40. Abbott Business Overview Table 41. Abbott Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abbott Skin Cancer Diagnostics Therapeutics Product Portfolio Table 43. Abbott Recent Development Table 44. Merck & Co., Inc. Company Information Table 45. Merck & Co., Inc. Business Overview Table 46. Merck & Co., Inc. Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Merck & Co., Inc. Skin Cancer Diagnostics Therapeutics Product Portfolio Table 48. Merck & Co., Inc. Recent Development Table 49. GlaxoSmithKline Company Information Table 50. GlaxoSmithKline Business Overview Table 51. GlaxoSmithKline Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. GlaxoSmithKline Skin Cancer Diagnostics Therapeutics Product Portfolio Table 53. GlaxoSmithKline Recent Development Table 54. Amgen Company Information Table 55. Amgen Business Overview Table 56. Amgen Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Amgen Skin Cancer Diagnostics Therapeutics Product Portfolio Table 58. Amgen Recent Development Table 59. Sun Pharmaceutical Industries Ltd. Company Information Table 60. Sun Pharmaceutical Industries Ltd. Business Overview Table 61. Sun Pharmaceutical Industries Ltd. Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sun Pharmaceutical Industries Ltd. Skin Cancer Diagnostics Therapeutics Product Portfolio Table 63. Sun Pharmaceutical Industries Ltd. Recent Development Table 64. Qiagen NV Company Information Table 65. Qiagen NV Business Overview Table 66. Qiagen NV Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Qiagen NV Skin Cancer Diagnostics Therapeutics Product Portfolio Table 68. Qiagen NV Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis AG Skin Cancer Diagnostics Therapeutics Product Portfolio Table 73. Novartis AG Recent Development Table 74. F. Hoffmann-La Roche Ltd Company Information Table 75. F. Hoffmann-La Roche Ltd Business Overview Table 76. F. Hoffmann-La Roche Ltd Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. F. Hoffmann-La Roche Ltd Skin Cancer Diagnostics Therapeutics Product Portfolio Table 78. F. Hoffmann-La Roche Ltd Recent Development Table 79. Bristol-Myers Squibb Company Company Information Table 80. Bristol-Myers Squibb Company Business Overview Table 81. Bristol-Myers Squibb Company Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Company Skin Cancer Diagnostics Therapeutics Product Portfolio Table 83. Bristol-Myers Squibb Company Recent Development Table 84. AstraZeneca PLC Company Information Table 85. AstraZeneca PLC Business Overview Table 86. AstraZeneca PLC Skin Cancer Diagnostics Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AstraZeneca PLC Skin Cancer Diagnostics Therapeutics Product Portfolio Table 88. AstraZeneca PLC Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Skin Cancer Diagnostics Therapeutics Product Image Figure 2. Global Skin Cancer Diagnostics Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Skin Cancer Diagnostics Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Skin Cancer Diagnostics Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Melanoma Image Figure 8. Non-melanoma Image Figure 9. Global Skin Cancer Diagnostics Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Skin Cancer Diagnostics Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Skin Cancer Diagnostics Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Skin Cancer Diagnostics Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Skin Cancer Diagnostics Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Skin Cancer Diagnostics Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Skin Cancer Diagnostics Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Skin Cancer Diagnostics Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Skin Cancer Diagnostics Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Skin Cancer Diagnostics Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Melanoma
  • Non-melanoma
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abbott
  • Merck & Co., Inc.
  • GlaxoSmithKline
  • Amgen
  • Sun Pharmaceutical Industries Ltd.
  • Qiagen NV
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Skin Cancer Diagnostics Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Skin Cancer Diagnostics Therapeutics Market Dynamics
  1. 2.1 Skin Cancer Diagnostics Therapeutics Industry Trends
  2. 2.2 Skin Cancer Diagnostics Therapeutics Industry Drivers
  3. 2.3 Skin Cancer Diagnostics Therapeutics Industry Opportunities and Challenges
  4. 2.4 Skin Cancer Diagnostics Therapeutics Industry Restraints
3 Skin Cancer Diagnostics Therapeutics Market by Company
  1. 3.1 Global Skin Cancer Diagnostics Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Skin Cancer Diagnostics Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Skin Cancer Diagnostics Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Skin Cancer Diagnostics Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Skin Cancer Diagnostics Therapeutics Company Product Type and Application
  6. 3.6 Global Skin Cancer Diagnostics Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Skin Cancer Diagnostics Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Skin Cancer Diagnostics Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Skin Cancer Diagnostics Therapeutics Market by Type
  1. 4.1 Skin Cancer Diagnostics Therapeutics Type Introduction
  2. 4.1.1 Melanoma
  3. 4.1.2 Non-melanoma
  4. 4.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Type
  5. 4.2.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Type (2021-2032)
5 Skin Cancer Diagnostics Therapeutics Market by Application
  1. 5.1 Skin Cancer Diagnostics Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Application
  6. 5.2.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Skin Cancer Diagnostics Therapeutics Sales Value Share by Application (2021-2032)
6 Skin Cancer Diagnostics Therapeutics Regional Value Analysis
  1. 6.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Skin Cancer Diagnostics Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Skin Cancer Diagnostics Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Skin Cancer Diagnostics Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Skin Cancer Diagnostics Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Skin Cancer Diagnostics Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Skin Cancer Diagnostics Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Skin Cancer Diagnostics Therapeutics Country-level Value Analysis
  1. 7.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Skin Cancer Diagnostics Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Skin Cancer Diagnostics Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Skin Cancer Diagnostics Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Skin Cancer Diagnostics Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Skin Cancer Diagnostics Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Skin Cancer Diagnostics Therapeutics Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Skin Cancer Diagnostics Therapeutics Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Skin Cancer Diagnostics Therapeutics Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Skin Cancer Diagnostics Therapeutics Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Sun Pharmaceutical Industries Ltd.
  26. 8.5.1 Sun Pharmaceutical Industries Ltd. Company Information
  27. 8.5.2 Sun Pharmaceutical Industries Ltd. Business Overview
  28. 8.5.3 Sun Pharmaceutical Industries Ltd. Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sun Pharmaceutical Industries Ltd. Skin Cancer Diagnostics Therapeutics Product Portfolio
  30. 8.5.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  31. 8.6 Qiagen NV
  32. 8.6.1 Qiagen NV Company Information
  33. 8.6.2 Qiagen NV Business Overview
  34. 8.6.3 Qiagen NV Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Qiagen NV Skin Cancer Diagnostics Therapeutics Product Portfolio
  36. 8.6.5 Qiagen NV Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG Skin Cancer Diagnostics Therapeutics Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
  43. 8.8 F. Hoffmann-La Roche Ltd
  44. 8.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 8.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Ltd Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Ltd Skin Cancer Diagnostics Therapeutics Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Skin Cancer Diagnostics Therapeutics Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 AstraZeneca PLC
  56. 8.10.1 AstraZeneca PLC Company Information
  57. 8.10.2 AstraZeneca PLC Business Overview
  58. 8.10.3 AstraZeneca PLC Skin Cancer Diagnostics Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca PLC Skin Cancer Diagnostics Therapeutics Product Portfolio
  60. 8.10.5 AstraZeneca PLC Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst